Phase I Trial In Painful Diabetic Peripheral Neuropathy

Executing an early‑phase neuropathy study demands precision, stability, and sustained participant support — especially when the protocol requires 18 consecutive overnight stays and tightly controlled BID dosing windows.

This Phase I program achieved full cohort enrollment within five months, meeting aggressive timelines while maintaining a fully representative PDPN population across key demographic groups. Intensive pharmacokinetic sampling across 16 timepoints added further operational pressure, yet the study maintained complete participant retention. That success stemmed from proactive engagement strategies, consistent in‑clinic guidance, and an environment built to minimize burden during extended confinement. The outcome demonstrates how structured operational planning and hands‑on support can keep even the most demanding early‑phase designs on schedule.

Access the full case study to explore the methods that sustained accuracy, retention, and demographic balance throughout the trial.